ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GSK Gsk Plc

1,636.00
0.00 (0.00%)
25 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1,636.00 1,638.00 1,639.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.69 67.46B

ADRs End Mostly Higher, H World and RedHill BioPharma Trade Actively

02/12/2022 10:37pm

Dow Jones News


Gsk (LSE:GSK)
Historical Stock Chart


From Apr 2022 to Apr 2024

Click Here for more Gsk Charts.

By Kathryn Hardison

 

International stocks trading in New York closed mostly higher Friday.

The S&P/BNY Mellon index of American depositary receipts rose 0.2% to 144.57. The European index moved 0.1% higher to 139.55, the Asian index rose 0.6% to 167.49, the Latin American index fell 0.1% to 189.44 and the emerging markets index increased 0.9% to 284.29.

H World Group Ltd. and RedHill Biopharma were among the companies with ADRs that traded actively.

ADRs of H World Group increased 5.9% on Friday following news that Hui Chen will step down as finance chief of the company, effective immediately. The company said Jihong He, its chief executive for international business, has been appointed as its new CFO.

ADRs of RedHill Biopharma dropped 27% after the company priced an $8 million underwritten public offering. The offering is expected to close Dec. 6.

ADRs of GSK PLC increased 0.9% after the pharmaceutical company said a Phase 3 trial for its Jemperli treatment for advanced or recurrent endometrial cancer met its primary endpoint, showing meaningful improvement in progression-free survival.

 

Write to Kathryn Hardison at kathryn.hardison@wsj.com

 

(END) Dow Jones Newswires

December 02, 2022 17:22 ET (22:22 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

1 Year Gsk Chart

1 Year Gsk Chart

1 Month Gsk Chart

1 Month Gsk Chart

Your Recent History

Delayed Upgrade Clock